China firm to launch new prostate cancer Dx
This article was originally published in Clinica
China Medical Technologies is to launch a new molecular diagnostic kit for prostate cancer in July 2008. The Prostate Cancer FISH (fluorescent in situ hybridization) Detection Kit detects TMPRSS2 and ETS gene fusions in prostate pathological tissues. Its methodology is based on research that shows these fusions to occur in approximately 80% of prostate cancer cases. This is said to indicate that the -application of TMPRSS2/ETS gene fusions as specific biomarkers can significantly increase the sensitivity for prostate cancer diagnosis", reports BioSpectrum Bureau.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.